Lornoxicam: A New Alternative of Choice for Effective Analgesia

Abstract

Lomoxicam is a new NSAIDs belonging to the enolic acid chemical class shared by piroxicam and tenoxicarn. It is rapidly eliminated, having short plasma elimination half-life of 3 - 5 hours which suggests its suitability for acute use in the postoperative period, in addition to its clinical efficacy in relieving chronic pain associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. As most of NSAIDs, it provides effective analgesia in patients with acute pain after minor and major surgery, either as a substitute for or as an adjunct to opioid analgesia. The major advantage of NSAIDs is that, compared with opioid analgesics, they are relatively well tolerated when used in selected patients for short-term postoperative analgesia. Many clinical studies also support such indication of lomoxicarn, so far.